SUCCESSFUL COST EFFECTIVE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR

被引：1
|
作者：
Halim, Medhat [1 ]
Alotaibi, Torki [1 ]
Gheith, Osama [2 ]
Adel, Hany [1 ]
Mosaad, Ahmed [1 ]
Abo-Atteya, Hassanein [1 ]
Zakareya, Zakareya [1 ]
Said, Tarek [1 ]
Nair, Prasad [1 ]
Nampoory, Naryanan [1 ]
机构：
[1] OTC, Nephrol, Kuwait, Kuwait
[2] MUNC, Nephrol, Kuwait, Kuwait
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv185.54
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP865
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients
    Len, Oscar
    Gavalda, Joan
    Aguado, Jose Maria
    Borrell, Nuria
    Cervera, Carlos
    Cisneros, Jose Miguel
    Cuervas-Mons, Valentin
    Gurgui, Merce
    Martin-Davila, Pilar
    Montejo, Miguel
    Munoz, Patricia
    Bou, German
    Carratala, Jordi
    Torre-Cisneros, Julian
    Pahissa, Albert
    CLINICAL INFECTIOUS DISEASES, 2008, 46 (01) : 20 - 27
  • [42] Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
    Takenaka, Katsuto
    Nagafuji, Koji
    Takase, Ken
    Kamimura, Tomohiko
    Mori, Yasuo
    Ito, Yoshikiyo
    Nishi, Yukiko
    Henzan, Hideho
    Kato, Koji
    Harada, Naoki
    Eto, Tetsuya
    Miyamoto, Toshihiro
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (01) : 94 - 100
  • [43] Low dose valganciclovir in liver transplant recipients.
    Dupuis, R
    Harris, M
    Andreoni, K
    Gerber, D
    Conoley, R
    Fair, J
    VanBeuge, D
    Johnson, M
    Watson, R
    Shrestha, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 167 - 167
  • [44] Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
    Katsuto Takenaka
    Koji Nagafuji
    Ken Takase
    Tomohiko Kamimura
    Yasuo Mori
    Yoshikiyo Ito
    Yukiko Nishi
    Hideho Henzan
    Koji Kato
    Naoki Harada
    Tetsuya Eto
    Toshihiro Miyamoto
    Takanori Teshima
    Koichi Akashi
    International Journal of Hematology, 2012, 96 : 94 - 100
  • [45] Standard-versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients.
    Wilson, N.
    Sulejmani, N.
    Jantz, A.
    Patel, A.
    Summers, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 532 - 532
  • [46] PREVENTION OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS
    PIDGEON, GB
    BAILEY, RR
    NEW ZEALAND MEDICAL JOURNAL, 1993, 106 (967) : 468 - 469
  • [47] PREVENTION OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS
    WINSTON, DJ
    LANCET, 1995, 346 (8987): : 1380 - 1381
  • [48] Prevention of cytomegalovirus disease in transplant recipients
    Snydman, DR
    Falagas, ME
    LANCET, 1996, 347 (8996): : 268 - 269
  • [49] Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. (vol 12, pg 112, 2006)
    Park, JM
    Lake, KD
    Arenas, JD
    Fontana, RJ
    LIVER TRANSPLANTATION, 2006, 12 (03) : 494 - 494
  • [50] Low Dose Valganciclovir Is an Effective Prophylaxis Against Cytomegalovirus in High Risk (Donor plus /Recipient-) Kidney Transplants Recipients
    Fayek, S.
    Beshears, E.
    Alvey, N.
    Sauer, A.
    Lieber, R.
    Olaitan, O.
    Hollinger, E.
    Jensik, S.
    Geyston, J.
    Brokhof, M.
    Hodowanec, A.
    Simon, D.
    Hertl, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
12345